{"disease":{"id":"chronic-kidney-disease","name":"Chronic kidney disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":5,"pipeline_drug_count":0,"trial_count":59},"drugs":{"marketed":[{"drug_id":"dapagliflozin","indication_name":"Chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Farxiga","generic_name":"DAPAGLIFLOZIN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor","quality_score":69,"revenue":"6300","mechanism":"Farxiga works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine."},{"drug_id":"canagliflozin","indication_name":"Chronic kidney disease (CKD) associated with type 2 diabetes (T2D)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Invokana","generic_name":"CANAGLIFLOZIN","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor","quality_score":71,"revenue":"800","mechanism":"Invokana works by blocking the SGLT2 protein in the kidneys to reduce glucose reabsorption."},{"drug_id":"finerenone","indication_name":"Chronic kidney disease (CKD) associated with type 2 diabetes (T2D)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kerendia","generic_name":"FINERENONE","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Mineralocorticoid receptor","drug_class":"Nonsteroidal Mineralocorticoid-Receptor Antagonist [EPC]","quality_score":59,"revenue":"600","mechanism":"Kerendia works by blocking the mineralocorticoid receptor, a protein that regulates sodium and potassium levels in the body."},{"drug_id":"roxadustat","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Evrenzo","generic_name":"ROXADUSTAT","company_name":"Astellas Pharma Europe B.V.","drug_phase":"marketed","molecular_target":"Thyroid hormone receptor beta","drug_class":"","quality_score":35,"revenue":"600","mechanism":""},{"drug_id":"retacrit","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epogen","generic_name":"Epoetin Alfa-Epbx","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating agent (ESA)","quality_score":10,"revenue":"400","mechanism":"Epoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin."},{"drug_id":"epoetin-alfa","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epogen","generic_name":"EPOETIN ALFA","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating Agent","quality_score":63,"revenue":"400","mechanism":"Epogen works by binding to the erythropoietin receptor, triggering a cascade of signals that stimulate the production of red blood cells."},{"drug_id":"epoetin-zeta","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Silapo","generic_name":"EPOETIN ZETA","company_name":"Hospira UK Limited","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"methoxy-polyethylene-glycol-epoetin-beta","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mircera","generic_name":"METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"erythropoietin receptor","drug_class":"","quality_score":49,"revenue":null,"mechanism":"Mircera activates erythropoietin receptors, increasing red cell production in response to hypoxia."},{"drug_id":"epogen","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Epogen","company_name":"Johns Hopkins University","drug_phase":"discontinued","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with chronic kidney disease.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"procrit","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Procrit","company_name":"University of Louisville","drug_phase":"discontinued","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"erythropoietin","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Erythropoietin","company_name":"Nanjing First Hospital, Nanjing Medical University","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":null},{"drug_id":"dapa","indication_name":"Chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAPA","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"epoetin-beta","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neorecormon","generic_name":"EPOETIN BETA","company_name":"Roche Registration Limited","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Neorecormon works by binding to the erythropoietin receptor, mimicking the action of natural erythropoietin to stimulate red blood cell production."},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"sotagliflozin","indication_name":"Chronic kidney disease at increased risk of cardiovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inpefa","generic_name":"SOTAGLIFLOZIN","company_name":"Lexicon Pharms Inc","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Inpefa works by blocking the sodium/glucose cotransporter 2 in the kidneys, reducing glucose reabsorption and lowering blood sugar levels."},{"drug_id":"forxiga","indication_name":"Chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Forxiga","company_name":"AstraZeneca Turkey","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"farxiga","indication_name":"Chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Farxiga","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"mircera","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mircera","company_name":"Samsung Medical Center","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"furosemide-injection","indication_name":"Edema in adults with chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Furosemide Injection","company_name":"Johannes Grand","drug_phase":"marketed","molecular_target":"","drug_class":"Loop Diuretic [EPC]","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"neorecormon","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neorecormon","company_name":"Centre Hospitalier Universitaire, Amiens","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"enarodustat","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enaroy","generic_name":"ENARODUSTAT","company_name":"Japan Tabacco","drug_phase":"marketed","molecular_target":"Egl nine homolog 1","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"dapaglifozin","indication_name":"Chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dapaglifozin","company_name":"MedImmune LLC","drug_phase":"phase_3","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"daprodustat","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jesduvroq","generic_name":"DAPRODUSTAT","company_name":"GSK","drug_phase":"marketed","molecular_target":"Egl nine homolog 1","drug_class":"Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Jesduvroq works by activating hypoxia-inducible factor prolyl hydroxylase inhibitors, which increases the production of erythropoietin, a hormone that stimulates red blood cell production."},{"drug_id":"nandrolone-decanoate","indication_name":"Anemia in chronic kidney disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nandrolone Decanoate","generic_name":"NANDROLONE DECANOATE","company_name":"Woodward Specl","drug_phase":"marketed","molecular_target":"Sex hormone-binding globulin","drug_class":"Androgen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"difelikefalin","indication_name":"Pruritus associated with chronic kidney disease (CKD-aP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Korsuva","generic_name":"DIFELIKEFALIN","company_name":"Vifor Intl","drug_phase":"marketed","molecular_target":"Kappa-type opioid receptor","drug_class":"Kappa Opioid Receptor Agonist","quality_score":48,"revenue":null,"mechanism":"Korsuva works by activating the kappa-type opioid receptor, which helps to reduce itching."}],"pipeline":[],"offLabel":[],"totalMarketed":28,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT04053335","title":"Smarter Care Virginia, Examining Low-Value Care in Virginia","phase":"","overall_status":"COMPLETED","enrollment_count":5000000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT06239129","title":"The Stockholm CREAtinine Measurements Project","phase":"","overall_status":"COMPLETED","enrollment_count":3200000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05932901","title":"OPTIMISE-CKD Drug Utilization","phase":"","overall_status":"COMPLETED","enrollment_count":2682052,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03084172","title":"Systemic Redesign and Demonstration for Early Detection, Evaluation and Management of Chronic Kidney Disease in Shanghai","phase":"","overall_status":"UNKNOWN","enrollment_count":2000000,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false},{"nct_id":"NCT04847531","title":"REVEAL-CKD: Prevalence and Consequences of Undiagnosed Chronic Kidney Disease","phase":"","overall_status":"COMPLETED","enrollment_count":1006361,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05914259","title":"An Observational Study to Learn More How Chronic Kidney Disease Gradually Changes Over Time in Adults Using Electronic Healthcare Records (CKD Natural History Study)","phase":"","overall_status":"COMPLETED","enrollment_count":969394,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05813652","title":"Relative Impacts on Preventative Primary Care--a Longitudinal Evaluation of COVID-19:Phase 1","phase":"","overall_status":"COMPLETED","enrollment_count":919928,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT05953701","title":"Secondary Data Analysis of Patients at Risk for CKD to Inspect CKD Prevalence, Diagnosis Rates, Diagnostic Behaviour, Treatment Patterns and Patient Characteristics","phase":"","overall_status":"COMPLETED","enrollment_count":800211,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04417725","title":"Burden of Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM), and Comorbid T2DM/CKD in Alberta, Canada","phase":"","overall_status":"COMPLETED","enrollment_count":588170,"lead_sponsor_name":"Medlior Health Outcomes Research Ltd","has_results":false},{"nct_id":"NCT05004428","title":"A Study to Learn More About Chronic Kidney Disease (CKD) in Patients With Type 2 Diabetes Mellitus (T2DM)","phase":"","overall_status":"COMPLETED","enrollment_count":336376,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06330480","title":"Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":320000,"lead_sponsor_name":"Prof. Dr. Folkert W. Asselbergs","has_results":false},{"nct_id":"NCT05248412","title":"The Long-term Spill-over Impact of COVID-19 on Health and Healthcare of People With Non-communicable Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":250000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT07093684","title":"Dementia and Kidney Disease: Epidemiological Approaches to Risk Factors and Treatment Strategies","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03958760","title":"Characteristics, Treatment, and Economic Burden of Patients With CVD,CKD or at High Cardiovascular Risk","phase":"","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT03987633","title":"EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Future Genetics Limited","has_results":false},{"nct_id":"NCT06608212","title":"An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06769646","title":"SPRING - Assess the Clinical Care Pathway of Population With T2D and CKD in Four European Countries Using Real-world Data","phase":"","overall_status":"COMPLETED","enrollment_count":110074,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05188885","title":"A Real World, Multi-centric, Observational Registry Study of Chronic Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":90000,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT04882813","title":"Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":87727,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05530291","title":"Incidence and Clinical Burden of Erythropoietin Hyporesponsiveness - a Retrospective Database Analysis","phase":"","overall_status":"COMPLETED","enrollment_count":85259,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT05225454","title":"The Life Style Patterns and the Development Trend of Chronic Diseases in Healthy and Sub-healthy Groups Were Analyzed by Using Data-mining Techniques","phase":"","overall_status":"UNKNOWN","enrollment_count":81108,"lead_sponsor_name":"Far Eastern Memorial Hospital","has_results":false},{"nct_id":"NCT05151003","title":"Epidemiology of In-hospital Acute Kidney Injury","phase":"","overall_status":"UNKNOWN","enrollment_count":60000,"lead_sponsor_name":"Universita degli Studi di Genova","has_results":false},{"nct_id":"NCT07217535","title":"Rutgers University Study of the Genetics of Kidney Disease","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT05497518","title":"The KidneyCARE (Community Access to Research Equity) Study","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Tufts Medical Center","has_results":false},{"nct_id":"NCT05526157","title":"An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":50000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06278207","title":"An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05015998","title":"A Study to Evaluate the ePidemiology of anEmia Associated With chroNic Kidney Disease in Patients in Primary Care Using The Stockholm CREAtinine Measurement (SCREAM) Register","phase":"","overall_status":"COMPLETED","enrollment_count":45637,"lead_sponsor_name":"Astellas Pharma Europe Ltd.","has_results":false},{"nct_id":"NCT03549754","title":"iCaReMe Global Registry","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07381101","title":"Trazodone and the Risk of Serious Adverse Events","phase":"","overall_status":"COMPLETED","enrollment_count":31459,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT06300086","title":"Nationwide Utilization of Danish Government Electronic Letter System for Increasing Guideline-directed Medical Therapy in Chronic Kidney Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":28388,"lead_sponsor_name":"Tor Biering-Sørensen","has_results":false},{"nct_id":"NCT01767883","title":"Improving Evidence-Based Primary Care for Chronic Kidney Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":27000,"lead_sponsor_name":"American Academy of Family Physicians","has_results":false},{"nct_id":"NCT03135002","title":"The Leicester City and County Chronic Kidney Disease Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":25000,"lead_sponsor_name":"University of Leicester","has_results":false},{"nct_id":"NCT00741585","title":"Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":21983,"lead_sponsor_name":"University of Vigo","has_results":false},{"nct_id":"NCT00960128","title":"Observational Prospective Study on Patients Treated With Norditropin®","phase":"","overall_status":"COMPLETED","enrollment_count":21249,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05169411","title":"Preserving Kidney Function in Children With Chronic Kidney Disease","phase":"","overall_status":"COMPLETED","enrollment_count":20240,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT03569735","title":"Nanshan Elderly Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07098416","title":"A Real-World Study About Anemia in Chronic Kidney Disease in China（DASHENG）","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Wei Chen","has_results":false},{"nct_id":"NCT02587936","title":"Improving Chronic Disease Management With Pieces","phase":"NA","overall_status":"COMPLETED","enrollment_count":18268,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":true},{"nct_id":"NCT06122961","title":"Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)","phase":"","overall_status":"COMPLETED","enrollment_count":18198,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05640180","title":"An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results","phase":"","overall_status":"COMPLETED","enrollment_count":17847,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06642272","title":"A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":17200,"lead_sponsor_name":"Herlev and Gentofte Hospital","has_results":false},{"nct_id":"NCT03228459","title":"The ILERVAS Project: Assessing the Prevalence of Subclinical Vascular Disease and Hidden Kidney Disease","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":16660,"lead_sponsor_name":"Institut de Recerca Biomèdica de Lleida","has_results":false},{"nct_id":"NCT03945968","title":"The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.","phase":"","overall_status":"RECRUITING","enrollment_count":16000,"lead_sponsor_name":"Russian Federation of Anesthesiologists and Reanimatologists","has_results":false},{"nct_id":"NCT05703880","title":"An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":15948,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07098078","title":"Domperidone and the Risk of Serious Adverse Events","phase":"","overall_status":"COMPLETED","enrollment_count":15000,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT07063316","title":"SGLT2 Inhibitors and Renal Anemia in Japan: RWD","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT04445181","title":"A Study Using the LMC Diabetes Registry to Learn More About Chronic Kidney Disease (CKD) in Canadian Patients With Type 2 Diabetes (T2D)","phase":"","overall_status":"COMPLETED","enrollment_count":14873,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03643601","title":"A Non-interventional, Epidemiological, Registry-based Evaluation of Anaemia in Swedish Patients With Chronic Kidney Disease","phase":"","overall_status":"COMPLETED","enrollment_count":14415,"lead_sponsor_name":"Astellas Pharma a/s","has_results":false},{"nct_id":"NCT07450820","title":"OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD","phase":"","overall_status":"RECRUITING","enrollment_count":14308,"lead_sponsor_name":"AstraZeneca","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}